Advances In The Clinical Postoperative Chemoradiotherapy Of Glioblastoma Multiforme

Glioma is the most common intracranial primary tumor, the World Health Organization(WHO) classified it into I-IV grades according to the pathological characteristic,and Glioblastoma multiforme(GBM) is about 50% of glioma. GBM is the most common pathological type of all,but has a highest death rate,because the operation is particularly difficult resul from the highly invasive of the tumor cell, it always mix with the normal tissue and difficult to be separated. Passed epidemiological studies had enough evidences to prove that the extent of resection, the patient’s age, physiclal status et al are prognostic factors of GBM. Recent years,studies of some molecular markers of GBM is more and more, some molecular prognostic factors are considered to impact the prognosis of GBM, and even probable to guide the individualized treatment. The treatment with radiotherapy with combined and adjuvant chemotherapy following operation is the standard treatment of GBM, and is more effective to improve overall survival. In recent years, some new molecular targeted drugs have provided a glimmer of hope to improve the survival of malignant glioma. At the same time,these treatments of chemotherapy combined with radiotherapy and targeted therapy lead to higher rate of pseudoprogression and Pseudoresponse,which are hard to distinguished from true progression,true response and radionecrosis. That interferes correct judgment on disease development and would affects the clinicians to determine the fuether treatment plan. Therefore, this paper discusses from prognosis, diagnosis, treatment, and other aspects of GBM in order to provide a reference for clinical practice.